Target intelligence / Profile preview

Hepatocyte nuclear factor 1 alpha (HNF1A)

Target
HNF1A
Molecular classification
Transcription factor, DNA-binding protein, Homeobox protein
01

Overview

Hepatocyte nuclear factor 1 alpha (HNF1A) is a DNA-binding transcription factor from the HNF1 homeobox protein family, encoded by the HNF1A gene on chromosome 12q24.2. It contains a dimerization domain, an atypical POU-homeodomain for DNA binding, and a C-terminal transactivation domain. HNF1A regulates the expression of liver-specific and pancreatic genes involved in glucose transport, metabolism, and insulin secretion, playing a central role in glucose and lipid homeostasis as well as cell differentiation in liver, kidney, and pancreas. Mutations in HNF1A cause monogenic diabetes (MODY3) and are implicated in hepatic tumors and increased cardiovascular risk. Although no approved therapeutics directly target HNF1A, knowledge of its mutation status guides clinical management, especially in diabetes subtypes where sulfonylurea treatment is effective.

Other names
Hepatocyte nuclear factor 1αHNF-1αHNF1A homeobox ATCF1transcription factor 1MODY3 gene
02

Mechanism of action

In MODY3, sulfonylureas increase insulin release from pancreatic β-cells with defective HNF1A-mediated transcription; therapy leverages the remaining β-cell function.

03

Biological functions

Regulation of glucose metabolismControl of hepatocyte and pancreatic gene expressionRegulation of insulin secretionRegulation of renal proximal tubular reabsorptionCell differentiationCellular homeostasis
04

Disease associations

Diabetes (particularly maturity-onset diabetes of the young type 3 / MODY3)Liver cancer (hepatocellular carcinoma)Hepatocellular adenomaKidney dysfunctionPancreatic dysfunctionCoronary artery disease
05

Safety considerations

Loss-of-function mutations result in severe early-onset diabetesincreased risk of developing hepatic and renal diseasespossible increased cancer riskno known direct drug-specific safety issues since not a classic receptor/target
06

Interacting drugs

Sulfonylureas (glucose-lowering agents used in MODY3)
07

Biomarkers

HNF1A mutations/genotyping (for MODY3 diagnosis and therapy selection)downregulation in liver tissue (biomarker in some liver tumors)impaired glucose tolerancedecreased C-peptide(genetic sequencing of HNF1A is key in MODY/MODY3 identification)

Beyond the preview

Go deeper on Hepatocyte nuclear factor 1 alpha (HNF1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatocyte nuclear factor 1 alpha (HNF1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call